Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 01 - 18 entities : Gilead sciences, inc. save search
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 2.5K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
GLPG | News | $28.77 -2.31% -2.33% 1.5K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
jyseleca treatment license ulcerative colitis
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
Published: 2022-01-18 (Crawled : 23:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 2.5K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
financial results ces results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.